Home Interim Data to Be Presented for MK-3475, Mercks Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma
 

Keywords :   


Interim Data to Be Presented for MK-3475, Mercks Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma

2013-11-15 23:00:00| Merck.com - Research & Development News

Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, will present additional data from patients with advanced melanoma from the Phase IB trial of MK-3475 on Monday, Nov. 18 at the 10th International Congress of the Society for Melanoma Research in Philadelphia. MK-3475 is Mercks investigational anti-PD-1 immunotherapy. Language: English Contact: MerckMedia:Ian McConnell, 908-423-3046orClaire Mulhearn, 908-423-7425orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: with data advanced presented

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
26.06Universal UK resort to open 365 days a year
26.06Eastern North Pacific Tropical Weather Outlook
26.06Atlantic Tropical Weather Outlook
26.06VW to invest up to $5bn in Tesla rival Rivian
26.06Strategic use of soybean meal to maximize hog carcass weight during summer
26.06Eastern North Pacific Tropical Weather Outlook
26.06Atlantic Tropical Weather Outlook
26.06Aer Lingus pilots begin industrial action over pay dispute
More »